China News Service, July 16, according to Reuters, the British medical journal Lancet (Lancet) said on July 15 local time that it was developed by the British-Swedish pharmaceutical giant AstraZeneca and Oxford University. The early clinical trial data of one of the vaccines will be published on July 20.
According to reports, this candidate vaccine is already undergoing a large-scale phase III clinical trial to assess whether it can resist the new coronavirus, but the developers have not yet reported the results of the first phase of the trial showing whether the vaccine is safe and whether it induces an immune response.
"We expect this paper, which is undergoing final editing and preparation, to be published on Monday, July 20, and immediately published." A spokesman for The Lancet said.
It is reported that before the "Lancet" issued a statement, it was reported earlier on the 15th that the data of the first phase of the trial may be released as early as the 16th.
According to previous reports in the media, AstraZeneca said that the phase 1/2 phase of the AZD1222 vaccine was launched on April 23 to evaluate the safety, immunogenicity and effectiveness of the vaccine; American media said in June that Slikon conducted a phase 3 clinical trial of the vaccine in the UK in August, which was the final step before the vaccine was approved by the regulatory authorities for marketing.